This company listing is no longer active
Resumen de acción MR4
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Meridian Bioscience, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.90 |
| 52 Week High | US$33.18 |
| 52 Week Low | US$18.52 |
| Beta | 0.23 |
| 1 Month Change | 0.26% |
| 3 Month Change | -5.99% |
| 1 Year Change | 63.75% |
| 3 Year Change | 312.00% |
| 5 Year Change | 160.98% |
| Change since IPO | 1,254.40% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| MR4 | DE Medical Equipment | Mercado DE | |
|---|---|---|---|
| 7D | 0.9% | -5.0% | -2.0% |
| 1Y | 63.8% | -13.6% | -0.3% |
Rentabilidad vs. Industria: MR4 exceeded the German Medical Equipment industry which returned -15.8% over the past year.
Rentabilidad vs. Mercado: MR4 exceeded the German Market which returned -11.9% over the past year.
Volatilidad de los precios
| MR4 volatility | |
|---|---|
| MR4 Average Weekly Movement | 2.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: MR4 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: MR4's weekly volatility (2%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1976 | 704 | Jack Kenny | www.meridianbioscience.com |
Resumen de fundamentos de Meridian Bioscience, Inc.
| Estadísticas fundamentales de MR4 | |
|---|---|
| Capitalización bursátil | €1.38b |
| Beneficios(TTM) | €39.06m |
| Ingresos (TTM) | €306.34m |
35.2x
Ratio precio-beneficio (PE)4.5x
Ratio precio-ventas (PS)¿Está MR4 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MR4 | |
|---|---|
| Ingresos | US$333.02m |
| Coste de los ingresos | US$144.66m |
| Beneficio bruto | US$188.36m |
| Otros gastos | US$145.90m |
| Beneficios | US$42.46m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.96 |
| Margen bruto | 56.56% |
| Margen de beneficio neto | 12.75% |
| Ratio deuda/patrimonio | 6.8% |
¿Cómo se ha desempeñado MR4 a largo plazo?
Ver rendimiento histórico y comparativa